Global Momentum and Validation Grows at AAIC for ALZpath Proprietary pTau217 Antibody Use in Alzheimer’s Disease Research, Diagnosis, and Treatment
ALZpath pTau217 antibody data included in 37 submissions at AAIC, building on 90 Publications Across 18 Countries demonstrating ALZpath’s superior sensitivity and accuracy in blood-based tests for Alzheimer’s disease CARLSBAD, Calif., July 28, 2025 – ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer’s disease, announced today that data highlighting the ALZpath pTau217 antibody […]
ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer’s Disease Diagnostics
The ALZpath Antibody is Integral to Advanced Blood Tests for Early Diagnosis of Alzheimer’s Disease and is Widely Available on Research and Clinical Testing Platforms CARLSBAD, California, April 7, 2025 — ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced it has been honored with the […]
Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis
Findings from Studies on Blood Tests Utilizing the ALZpath pTau217 Antibody – Integral to Many Advanced Assays for Research and Clinical Use – Featured in Seven Oral Presentations and Two Posters CARLSBAD, California, April 1, 2025 — ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced […]
ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor
Samantha Budd Haeberlein, PhD, Joins the Board; Henrik Zetterberg, MD, PhD, Extends Advisory Role, Adding to a Preeminent Group of Multi-Disciplinary Experts Guiding ALZpath’s Innovation Initiatives CARLSBAD, California, March 25, 2025 — ALZpath, Inc., a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced the addition of Samantha Budd Haeberlein, PhD, […]
ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
CARLSBAD, California, March 18, 2025 — ALZpath, Inc.,a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced that it has been named to Fast Company‘s prestigious list of the World’s Most Innovative Companies of 2025. Alzheimer’s disease and related dementias are expected to impact nearly 153 million people globally by […]
ALZpath Appoints Mike Banville as CEO
CARLSBAD, California, January 27, 2025 — ALZpath, Inc., a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced the board’s appointment of Mike Banville as CEO, effective January 1. Banville replaces Chad Holland, who served in a fractional role as CEO while ALZpath transitioned toward its next stage of development. […]
Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research
MINNEAPOLIS, November 18, 2024 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer’s disease. The collaboration leverages Bio-Techne’s Ella™ fully automated, multiplexing immunoassay platform and ALZpath’s proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay. […]
ALZpath Proprietary pTau217 Antibody Named to TIME’S List of the Best Inventions of 2024
CARLSBAD, Calif., Oct. 30, 2024 /PRNewswire/ — ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced that it has been honored in TIME’s annual Best Inventions list, which features 200 extraordinary innovations changing our lives. The ALZpath proprietary pTau 217 antibody was recognized in the medical […]
New Data Presented at AAIC 2024 Demonstrates High Accuracy of Blood Tests Incorporating ALZpath Proprietary pTau217 Antibody for Alzheimer’s Disease Diagnosis
Study Showed High Accuracy in Determining Amyloid Burden Across All Stages of Alzheimer’s Disease Progression, Supporting Early Detection, Treatment, Interventions and Tracking ALZpath pTau217 Antibody Has Now Been Utilized in Over 40 Cohort Studies with 50,000 Samples CARLSBAD, California, July 29, 2024 – ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for […]
ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease
Beckman Coulter to Utilize the ALZpath pTau217 Antibody to Detect Key Biomarker for Alzheimer’s Disease on its DxI 9000 Immunoassay Analyzer July 15, 2024 – ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, announced today that it has signed a licensing agreement with Beckman Coulter Diagnostics, […]